Bristol-Myers Squibb is trading at $70.24 (7.6% up) today following a strong Q2 2026 earnings report and a substantial full-year guidance raise.
- Management highlighted accelerating growth from newer drugs and a surge in Eliquis sales, signaling strong operational momentum.
- The company's Growth Portfolio is now more than offsetting revenue erosion from legacy products, driving renewed investor optimism regarding the long-term pipeline.